BackHeidelberg Pharma AG Overview
Heidelberg Pharma AG

Heidelberg Pharma AG Return on Equity

Heidelberg Pharma AG (HPHA.DE) has a ROE of 154.75%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

154.75%

Return on Equity

154.75%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Heidelberg Pharma AG (HPHA.DE) FAQ

As of the most recent data, HPHA.DE shows a ROE of 154.75%. That is above the Healthcare sector average of 13.1%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about 13.1%. Heidelberg Pharma AG is at 154.75%, which is higher that average. That is roughly 1081.0% above the sector mean. Use the comparison chart on this page to see how HPHA.DE stacks up against individual peers as well.

Check the historical chart to see whether HPHA.DE's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Heidelberg Pharma AG with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Heidelberg Pharma AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 154.75%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about 13.1%, while HPHA.DE is at 154.75%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.